- Home
- OVID vs ASRT Comparison
OVID vs ASRT Comparison
Compare OVID & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVID
- ASRT
- Stock Information
- Founded
- OVID 2014
- ASRT 1995
- Country
- OVID United States
- ASRT United States
- Employees
- OVID N/A
- ASRT N/A
- Industry
- OVID Biotechnology: Pharmaceutical Preparations
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- OVID Health Care
- ASRT Health Care
- Exchange
- OVID Nasdaq
- ASRT Nasdaq
- Market Cap
- OVID 88.9M
- ASRT 79.1M
- IPO Year
- OVID 2017
- ASRT 1997
- Fundamental
- Price
- OVID $1.48
- ASRT $0.80
- Analyst Decision
- OVID Strong Buy
- ASRT Strong Buy
- Analyst Count
- OVID 4
- ASRT 1
- Target Price
- OVID $3.13
- ASRT $3.00
- AVG Volume (30 Days)
- OVID 5.7M
- ASRT 248.3K
- Earning Date
- OVID 11-11-2025
- ASRT 11-10-2025
- Dividend Yield
- OVID N/A
- ASRT N/A
- EPS Growth
- OVID N/A
- ASRT N/A
- EPS
- OVID N/A
- ASRT N/A
- Revenue
- OVID $6,651,000.00
- ASRT $117,099,000.00
- Revenue This Year
- OVID $1,086.57
- ASRT N/A
- Revenue Next Year
- OVID N/A
- ASRT $4.10
- P/E Ratio
- OVID N/A
- ASRT N/A
- Revenue Growth
- OVID 1070.95
- ASRT N/A
- 52 Week Low
- OVID $0.24
- ASRT $0.51
- 52 Week High
- OVID $2.01
- ASRT $1.16
- Technical
- Relative Strength Index (RSI)
- OVID 50.82
- ASRT 38.83
- Support Level
- OVID $1.53
- ASRT $0.79
- Resistance Level
- OVID $1.79
- ASRT $0.88
- Average True Range (ATR)
- OVID 0.18
- ASRT 0.04
- MACD
- OVID -0.03
- ASRT -0.01
- Stochastic Oscillator
- OVID 34.42
- ASRT 10.35
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.